Literature DB >> 25650144

Cognitive profile of LRRK2-related Parkinson's disease.

Sindhu Srivatsal1, Brenna Cholerton, James B Leverenz, Zbigniew K Wszolek, Ryan J Uitti, Dennis W Dickson, Daniel Weintraub, John Q Trojanowski, Vivianna M Van Deerlin, Joseph F Quinn, Kathryn A Chung, Amie L Peterson, Stewart A Factor, Cathy Wood-Siverio, Jennifer G Goldman, Glenn T Stebbins, Bryan Bernard, Beate Ritz, Rebecca Rausch, Alberto J Espay, Fredy J Revilla, Johnna Devoto, Liana S Rosenthal, Ted M Dawson, Marilyn S Albert, Ignacio F Mata, Shu-Ching Hu, Kathleen S Montine, Catherine Johnson, Thomas J Montine, Karen L Edwards, Jing Zhang, Cyrus P Zabetian.   

Abstract

BACKGROUND: Increasing evidence suggests that genetic factors play a role in the variability associated with cognitive performance in Parkinson's disease (PD). Mutations in the LRRK2 gene are the most common cause of monogenic PD; however, the cognitive profile of LRRK2-related PD is not well-characterized.
METHODS: A cohort of 1,447 PD patients enrolled in the PD Cognitive Genetics Consortium was screened for LRRK2 mutations and completed detailed cognitive testing. Associations between mutation carrier status and cognitive test scores were assessed using linear regression models.
RESULTS: LRRK2 mutation carriers (n = 29) demonstrated better performance on the Mini Mental State Examination (P = 0.03) and the Letter-Number Sequencing Test (P = 0.005). A smaller proportion of LRRK2 carriers were demented (P = 0.03).
CONCLUSIONS: Our cross-sectional study demonstrates better performance on certain cognitive tests, as well as lower rates of dementia in LRRK2-related PD. Future longitudinal studies are needed to determine whether LRRK2 mutation carriers exhibit slower cognitive decline.
© 2015 International Parkinson and Movement Disorder Society. © 2015 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  LRRK2; Parkinson's disease; cognition; neuropsychological tests; working memory

Mesh:

Substances:

Year:  2015        PMID: 25650144      PMCID: PMC4397146          DOI: 10.1002/mds.26161

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  32 in total

1.  Neuropathology of dementia in Parkinson's disease: a prospective, community-based study.

Authors:  Dag Aarsland; Robert Perry; Andrew Brown; Jan P Larsen; Clive Ballard
Journal:  Ann Neurol       Date:  2005-11       Impact factor: 10.422

2.  Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease.

Authors:  Jennifer G Goldman; Samantha Holden; Bryan Bernard; Bichun Ouyang; Christopher G Goetz; Glenn T Stebbins
Journal:  Mov Disord       Date:  2013-10-09       Impact factor: 10.338

3.  Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease.

Authors:  Roy N Alcalay; Helen Mejia-Santana; Ming X Tang; Brian Rakitin; Llency Rosado; Barbara Ross; Miguel Verbitsky; Sergey Kisselev; Elan D Louis; Cynthia L Comella; Amy Colcher; Danna Jennings; Martha A Nance; Susan Bressman; William K Scott; Caroline Tanner; Susan F Mickel; Howard F Andrews; Cheryl H Waters; Stanley Fahn; Lucien J Cote; Steven J Frucht; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Laura Marsh; Bradley Hiner; Andrew Siderowf; Ruth Ottman; Lorraine N Clark; Karen S Marder; Elise Caccappolo
Journal:  J Clin Exp Neuropsychol       Date:  2010-02-24       Impact factor: 2.475

4.  Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation.

Authors:  Gilad Yahalom; Yael Orlev; Oren S Cohen; Evgenia Kozlova; Eitan Friedman; Rivka Inzelberg; Sharon Hassin-Baer
Journal:  Mov Disord       Date:  2014-06-05       Impact factor: 10.338

5.  LRRK2 G2019S mutation in Parkinson's disease: a neuropsychological and neuropsychiatric study in a large Algerian cohort.

Authors:  Soreya Belarbi; Nassima Hecham; Suzanne Lesage; Mohamed I Kediha; Nourredine Smail; Traki Benhassine; Farida Ysmail-Dahlouk; Ebba Lohman; Badia Benhabyles; Tarik Hamadouche; Salima Assami; Alexis Brice; Meriem Tazir
Journal:  Parkinsonism Relat Disord       Date:  2010-10-08       Impact factor: 4.891

Review 6.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Authors:  W R Gibb; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

7.  Clinical features of LRRK2-associated Parkinson's disease in central Norway.

Authors:  Jan O Aasly; Mathias Toft; Ignacio Fernandez-Mata; Jennifer Kachergus; Mary Hulihan; Linda R White; Matthew Farrer
Journal:  Ann Neurol       Date:  2005-05       Impact factor: 10.422

8.  APOE ε4 increases risk for dementia in pure synucleinopathies.

Authors:  Debby Tsuang; James B Leverenz; Oscar L Lopez; Ronald L Hamilton; David A Bennett; Julie A Schneider; Aron S Buchman; Eric B Larson; Paul K Crane; Jeffrey A Kaye; Patricia Kramer; Randy Woltjer; John Q Trojanowski; Daniel Weintraub; Alice S Chen-Plotkin; David J Irwin; Jacqueline Rick; Gerard D Schellenberg; G Stennis Watson; Walter Kukull; Peter T Nelson; Gregory A Jicha; Janna H Neltner; Doug Galasko; Eliezer Masliah; Joseph F Quinn; Kathryn A Chung; Dora Yearout; Ignacio F Mata; Jia Y Wan; Karen L Edwards; Thomas J Montine; Cyrus P Zabetian
Journal:  JAMA Neurol       Date:  2013-02       Impact factor: 18.302

9.  Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations.

Authors:  Lama M Chahine; Judy Qiang; Emily Ashbridge; James Minger; Dora Yearout; Stacy Horn; Amy Colcher; Howard I Hurtig; Virginia M-Y Lee; Vivianna M Van Deerlin; James B Leverenz; Andrew D Siderowf; John Q Trojanowski; Cyrus P Zabetian; Alice Chen-Plotkin
Journal:  JAMA Neurol       Date:  2013-07       Impact factor: 18.302

10.  LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample.

Authors:  Stefano Goldwurm; Michela Zini; Alessio Di Fonzo; Danilo De Gaspari; Chiara Siri; Erik J Simons; Marina van Doeselaar; Silvana Tesei; Angelo Antonini; Margherita Canesi; Anna Zecchinelli; Claudio Mariani; Nicoletta Meucci; Giorgio Sacilotto; Roberto Cilia; Ioannis U Isaias; A Bonetti; Francesca Sironi; Sara Ricca; Ben A Oostra; Vincenzo Bonifati; Gianni Pezzoli
Journal:  Parkinsonism Relat Disord       Date:  2006-06-05       Impact factor: 4.891

View more
  27 in total

Review 1.  Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease.

Authors:  Jennifer G Goldman; Neelum T Aggarwal; Cynthia D Schroeder
Journal:  Neurodegener Dis Manag       Date:  2015-10-30

2.  Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.

Authors:  Steven A Gunzler; David E Riley; Shu G Chen; Curtis M Tatsuoka; William M Johnson; John J Mieyal; Ellen M Walter; Christina M Whitney; I Jung Feng; Harry Owusu-Dapaah; Shivam O Mittal; Amy L Wilson-Delfosse
Journal:  J Neurol Sci       Date:  2018-03-17       Impact factor: 3.181

Review 3.  Integrating Patient Concerns into Parkinson's Disease Management.

Authors:  Shen-Yang Lim; Ai Huey Tan; Susan H Fox; Andrew H Evans; Soon Chai Low
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

Review 4.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

5.  Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease.

Authors:  Ignacio F Mata; Catherine O Johnson; James B Leverenz; Daniel Weintraub; John Q Trojanowski; Vivianna M Van Deerlin; Beate Ritz; Rebecca Rausch; Stewart A Factor; Cathy Wood-Siverio; Joseph F Quinn; Kathryn A Chung; Amie L Peterson-Hiller; Alberto J Espay; Fredy J Revilla; Johnna Devoto; Dora Yearout; Shu-Ching Hu; Brenna A Cholerton; Thomas J Montine; Karen L Edwards; Cyrus P Zabetian
Journal:  Neurobiol Aging       Date:  2017-04-20       Impact factor: 4.673

6.  A Personalized Approach to Parkinson's Disease Patients Based on Founder Mutation Analysis.

Authors:  Nir Giladi; Anat Mirelman; Avner Thaler; Avi Orr-Urtreger
Journal:  Front Neurol       Date:  2016-05-10       Impact factor: 4.003

Review 7.  Precision Medicine: Clarity for the Complexity of Dementia.

Authors:  Brenna Cholerton; Eric B Larson; Joseph F Quinn; Cyrus P Zabetian; Ignacio F Mata; C Dirk Keene; Margaret Flanagan; Paul K Crane; Thomas J Grabowski; Kathleen S Montine; Thomas J Montine
Journal:  Am J Pathol       Date:  2015-12-24       Impact factor: 4.307

8.  LRRK2 variation and dementia with Lewy bodies.

Authors:  Michael G Heckman; Alexandra I Soto-Ortolaza; Monica Y Sanchez Contreras; Melissa E Murray; Otto Pedraza; Nancy N Diehl; Ronald Walton; Catherine Labbé; Oswaldo Lorenzo-Betancor; Ryan J Uitti; Jay van Gerpen; Nilüfer Ertekin-Taner; Glenn E Smith; Kejal Kantarci; Rodolfo Savica; David T Jones; Jonathan Graff-Radford; David S Knopman; Val J Lowe; Clifford R Jack; Ronald C Petersen; Joseph E Parisi; Rosa Rademakers; Zbigniew K Wszolek; Neill R Graff-Radford; Tanis J Ferman; Dennis W Dickson; Bradley F Boeve; Owen A Ross
Journal:  Parkinsonism Relat Disord       Date:  2016-07-29       Impact factor: 4.891

9.  APOE, MAPT, and COMT and Parkinson's Disease Susceptibility and Cognitive Symptom Progression.

Authors:  Kimberly C Paul; Rebecca Rausch; Michelle M Creek; Janet S Sinsheimer; Jeff M Bronstein; Yvette Bordelon; Beate Ritz
Journal:  J Parkinsons Dis       Date:  2016-04-02       Impact factor: 5.568

10.  The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.

Authors:  Shu-Ying Liu; Daryl J Wile; Jessie Fanglu Fu; Jason Valerio; Elham Shahinfard; Siobhan McCormick; Rostom Mabrouk; Nasim Vafai; Jess McKenzie; Nicole Neilson; Alexandra Perez-Soriano; Julieta E Arena; Mariya Cherkasova; Piu Chan; Jing Zhang; Cyrus P Zabetian; Jan O Aasly; Zbigniew K Wszolek; Martin J McKeown; Michael J Adam; Thomas J Ruth; Michael Schulzer; Vesna Sossi; A Jon Stoessl
Journal:  Lancet Neurol       Date:  2018-02-16       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.